二、 公司控股股东及其一致行动人股份累计质押的情况 截至公告披露日，公司控股股东西藏新产业及实际控制人翁先定先生所持质 1 证券代码：300832 证券简称：新产业 公告编号：2025-046 深圳市新产业生物医学工程股份有限公司 关于控股股东部分质押股份办理延期购回手续的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市新产业生物医学工程股份有限公司（以下简称"公司"）于近日收到 公司控股股东西藏新产业投资管理有限公司（以下简称"西藏新产业"）的函告， 获悉西藏新产业所持有的公司 660 万股（含补充质押 110 万股）质押股份办理了 延期购回手续。具体事项如下： 上述办理延期购回手续的质押股份相关情况请参见公司分别于 2024 年 7 月 30 日、2025 年 4 月 10 日在巨潮资讯网披露的《关于控股股东部分股份办理质押 及解除质押的公告》（公告编号：2024-052）、《关于控股股东部分股份办理补 充质押的公告》（公告编号：2025-017）。 股东 名称 是否为 控股股 东或第 一大股 东及其 一致行 动人 办理延期 购回的质 押股份数 ...

Performance Review - Company reported 1Q25 financial data: revenue of 5.876 billion yuan, a year-on-year increase of 14.6%, gross profit of 1.428 billion yuan, a year-on-year increase of 11.8%, and net profit attributable to shareholders of 635 million yuan, a year-on-year increase of 23.2%, meeting expectations [1]. Development Trends Mining Equipment - Domestic demand remains resilient, with positive outlook for overseas expansion of mining trucks. Domestic coal prices are in a downward trend due to weak demand. Current demand for tunneling machines and wide-body trucks is strong, while hydraulic support prices are under intense competition. The company expects good growth for overseas wide-body trucks and large mining trucks, driven by product upgrades and reduced overall user costs, indicating significant long-term growth potential in large mining trucks and related aftermarket [1]. Logistics Equipment - Demand for port machinery is on the rise, with expansion of new products overseas. Starting in 2023, global demand for port equipment is recovering, with full orders for large port machinery and gradually strengthening order profitability. Exports of small port machinery products remain robust in Asia, Africa, and Latin America. Over the past three years, the company has aggressively expanded new products like telescopic forklifts in the European and American markets, currently producing in India to address tariff issues. The company is optimistic about the trend towards electrification of small port machinery and the continued expansion of new products overseas [1]. Oil and Gas Equipment - Demand and profitability are expected to recover. In 2024, revenue and profitability declined due to major clients' cost-cutting measures. The company anticipates marginal recovery in industry demand in 2025, with strengthened internal management to restore market share [2]. New Industries - Focus on cost reduction and efficiency improvement, expanding overseas application scenarios. In 2024, the company will enhance management reforms for new industries, readjusting businesses with intense competition and limited profitability. It is expected that operating losses in new industries will significantly narrow in 2025, optimizing the efficiency and return rate of existing assets [2]. Profit Forecast and Valuation - The company maintains the 2025 EPS forecast at 0.70 yuan and introduces the 2026 EPS forecast at 0.81 yuan. The current stock price corresponds to 7.9x/6.7x P/E for 2025/2026. Considering the improvement prospects in new industry profitability, the target price is raised by 25% to 7.10 HKD, corresponding to 9.5x/8.1x P/E for 2025/2026, indicating a 21% upside potential, maintaining an outperform rating [2].

Core Viewpoint - The China Securities Index for Healthcare Equipment and Services has shown a mixed performance, with a recent decline despite a slight year-to-date increase, indicating volatility in the healthcare sector [1]. Group 1: Index Performance - The CSI Healthcare Equipment and Services Index decreased by 0.29% to 13723.04 points, with a trading volume of 15.888 billion yuan [1]. - Over the past month, the index has increased by 5.01%, but it has decreased by 3.91% over the last three months, and it has risen by 0.54% year-to-date [1]. Group 2: Index Composition - The index is composed of listed companies in the healthcare sector, reflecting the overall performance of these companies [1]. - The top ten weighted companies in the index include Mindray Medical (9.76%), Aier Eye Hospital (7.89%), and United Imaging Healthcare (7.59%) [1]. - The index is primarily composed of companies listed on the Shenzhen Stock Exchange (60.77%) and the Shanghai Stock Exchange (39.23%) [1]. Group 3: Sample Adjustment and Fund Tracking - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December [2]. - Public funds tracking the healthcare index include several funds from Southern Asset Management and Tianhong Asset Management, among others [2].

Group 1 - Over 200 foreign institutions have conducted research on A-share listed companies since May, totaling more than 500 investigations, with a focus on hard technology sectors such as electronic devices and integrated circuits [1] - Notable foreign institutions involved in the research include Goldman Sachs, Fidelity, BlackRock, UBS, Allianz, and Point72, with companies like Aopu Technology, Lanke Technology, Hudian Co., and Aobi Zhongguang attracting over 30 foreign institution investigations each [1] - Point72, referred to as "Wall Street's craziest money-making machine," led the research activities with 17 investigations, focusing on companies such as Huace Testing, Miaoke Landuo, and Ruixin Micro [1] Group 2 - In addition to electronic devices and integrated circuits, sectors such as healthcare, industrial machinery, and electronic components have also garnered significant attention from foreign institutions, with industry leaders like BeiGene, Huichuan Technology, New Industry, and Shenzhen South Circuit receiving the most investigations [2] - Multiple foreign giants believe that the A-share market presents abundant investment opportunities, particularly in the technology growth sector, with Morgan Stanley highlighting key areas such as technology growth, Chinese manufacturing, and new consumption as worthy of attention [3] - Morgan Asset Management is optimistic about sectors including leading automotive manufacturers and components, AI-related industries, robotics, trendy toys, and pet-related businesses [3]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5] Core Insights - The blood purification device industry is benefiting from an aging population and increasing treatment penetration rates, with hemodialysis being the primary treatment for end-stage renal disease (ESRD) [2][12] - The domestic substitution trend in the blood purification device industry is accelerating, with local brands gradually rising to compete with foreign brands [2][33] - The market for blood purification devices is expected to grow significantly, driven by the increasing number of ESRD patients and the low treatment penetration rate in China compared to developed countries [17][19] Summary by Sections Market Performance - The pharmaceutical sector outperformed the overall market, with a 2.21% increase in the biopharmaceutical sector, while the total A-share market declined by 0.05% [1][60] - The TTM price-to-earnings ratio for the biopharmaceutical sector is 34.03x, which is at the 69.61% percentile of the historical valuation over the past five years [1][67] Industry Analysis - The global ESRD patient population is projected to grow from 1113.86 million in 2023 to 1328.60 million by 2027, with a compound annual growth rate (CAGR) of 4.51% [17] - In China, the number of ESRD patients receiving dialysis treatment is significantly lower than in developed countries, indicating substantial growth potential for treatment penetration [19][30] Competitive Landscape - Foreign brands dominate the blood purification device market, with companies like Fresenius and Baxter holding significant market shares, but local brands are increasingly gaining ground [33][37] - Major domestic players include Weigao Blood Purification, Shanda Mountain, and Jianfan Biological, which are expanding their market presence through innovation and product development [33][41][45] Company Forecasts and Ratings - Major companies in the sector, such as Mindray Medical and WuXi AppTec, are rated as "Outperform" with strong projected earnings growth over the next few years [4][71] - Weigao Blood Purification is expected to generate revenue of 36.04 billion yuan in 2024, with a leading market share in blood purification devices [38][41]

Group 1 - The National Enterprise Win ETF (159719) has seen a slight increase of 0.07%, with a latest price of 1.52 yuan as of June 3, 2025, and a cumulative increase of 0.66% over the past week as of May 30, 2025 [1] - The liquidity of the National Enterprise Win ETF shows a turnover of 2.19% with a transaction volume of 2.4277 million yuan, and an average daily transaction volume of 17.576 million yuan over the past year [1] - The CSI Guangdong-Hong Kong-Macao Greater Bay Area Development Theme Index (931000) has increased by 0.24%, with notable increases in constituent stocks such as Steady Medical (10.23%) and Zhongke Feimeng (6.42%) as of June 3, 2025 [3] Group 2 - A recent notice emphasizes the need to optimize the salary distribution for skilled positions in state-owned enterprises, linking salary to job value and skill level, and establishing a special allowance for skilled talents [4] - The notice also proposes a mechanism for salary growth for skilled talents, encouraging companies to adopt diversified incentive methods and establish a talent evaluation system based on innovation and contribution [4] - The central enterprises are accelerating their development in strategic emerging industries, with state-owned capital investment companies focusing on key areas and increasing their investment in new industries [5] Group 3 - The National Enterprise Win ETF closely tracks the FTSE China National Enterprise Open Win Index, which consists of 100 constituent stocks, including major "China National" stocks like China Petroleum and China Mobile [5] - The Greater Bay Area ETF tracks the CSI Guangdong-Hong Kong-Macao Greater Bay Area Development Theme Index, with the top ten weighted stocks accounting for 53.21% of the index, including companies like BYD and Ping An Insurance [5]

Core Viewpoint - The provincial government has issued the "Implementation Opinions" to actively and orderly undertake the transfer of manufacturing industries, aiming to accelerate the construction of a modern industrial system and promote regional coordinated development [1][2]. Group 1: Key Industries and Focus Areas - The province will tailor its approach to undertake key industrial transfers, focusing on the integration of energy materials and manufacturing industries, supporting the development of fine chemicals and high-end daily chemical products [1]. - In the equipment manufacturing sector, the focus will be on intelligent coal machinery, rail transit equipment, new energy equipment, and energy-saving environmental protection equipment, with an aim to enhance the technical level of complete products and basic components [1]. - The electronic information industry will prioritize semiconductors, information technology innovation, computing power, and photovoltaics, actively developing electronic information and related supporting industries, while incubating and nurturing technology-based SMEs and innovative enterprises [1]. Group 2: Industrial Layout and Development Strategy - The "Implementation Opinions" emphasize concentrated layout and promote industrial agglomeration development, strengthening various industrial undertaking platforms and guiding industries to gather in economic and technological development zones, high-tech industrial development zones, chemical parks, and specialized towns [1]. - The strategy includes promoting high-quality industrial transfer in central cities and urban agglomerations, while encouraging special types of regions to undertake the development of characteristic industries [1]. Group 3: Cooperation and Policy Framework - To facilitate industrial transfer cooperation, the "Implementation Opinions" propose innovative cooperation models, including cross-regional manufacturing transfer benefit-sharing mechanisms and "government + chain leader + park" investment attraction [2]. - The province aims to accelerate the establishment of free trade pilot zones and leverage international cooperation industrial parks, processing trade industrial parks, bonded zones, and dry ports to undertake gradient transfer of processing trade [2]. - The implementation of industrial transfer will be supported by improving the service system, strengthening the guarantee of industrial undertaking factors, and refining the work promotion mechanism to optimize the policy environment for undertaking manufacturing transfers [2].

Economic Overview - In April, the economic operation of Zhengzhou continued to show a stable and positive development trend, supported by the implementation of various reform tasks and policy measures [1][3] Industrial Production - The industrial added value of above-scale enterprises in Zhengzhou increased by 8.1% year-on-year in April, with nearly 70% of the 37 major industrial categories maintaining production growth [1] - The new materials industry, automotive manufacturing, and electronic information industries saw significant growth, with added values increasing by 16.1%, 13.9%, and 12.3% respectively, contributing a total of 66.5% to the above-scale industrial growth [1] Investment Growth - From January to April, fixed asset investment in Zhengzhou grew by 5.4% year-on-year, accelerating by 1.7 percentage points compared to the first quarter [1] - Investment in major projects (excluding real estate development) increased by 19.5% year-on-year, with a 4 percentage point acceleration from the first quarter [1] - Private investment showed significant support, growing by 12.5% year-on-year and contributing 7.2 percentage points to overall investment growth, maintaining double-digit growth for four consecutive months [1] Consumer Market - The total retail sales of social consumer goods reached 50.7 billion yuan in April, marking a year-on-year increase of 6.7% [2] - Retail sales through public networks increased by 34.1% year-on-year, continuing a trend of double-digit growth for eight consecutive months [2] - The retail sales of certain categories, such as computers and home appliances, saw substantial increases, with growth rates of 2.3 times, 1.4 times, and 45.4% respectively [2] New Industries and Technologies - The added value of high-tech manufacturing in Zhengzhou increased by 11.3% year-on-year in April, indicating rapid growth in new industries [2] - The production of new products such as integrated circuits, lithium-ion batteries, sensors, and new energy vehicles saw year-on-year increases of 51.5%, 68.4%, 42.2%, and 19.3% respectively [2] - Investment in high-tech manufacturing grew by 30.3% year-on-year from January to April, reflecting a positive investment trend in new industries [2] Future Outlook - The overall economic indicators in April showed a stable and positive trend, but there is a need to enhance the momentum for sustained economic recovery amid a complex external environment [3] - Future strategies will focus on stabilizing production, expanding domestic demand, and fostering new productive forces to promote continuous economic improvement [3]

Core Viewpoint - State-owned enterprises (SOEs) are accelerating investments in strategic emerging industries, focusing on key areas and enhancing their competitive edge through precise layouts and differentiated development [1][2]. Group 1: Investment Trends - SOEs have increased their investment in strategic emerging industries, with a reported year-on-year growth of 6.6% in the first quarter of this year [2]. - By 2025, the revenue from strategic emerging industries is expected to account for 35% of central enterprises' total revenue [2]. - Major projects in renewable energy, such as the 100 MW wind power project and the 400 MW offshore photovoltaic project, have been successfully connected to the grid, indicating significant progress in technology application and scale construction [2]. Group 2: Capital Empowerment - State-owned capital investment and operation companies are building an ecosystem for strategic emerging industries, with China Chengtong managing 71% of its total investment in these sectors [3]. - The "Chengtong Science and Technology Investment Fund" has been established with an initial scale of 10 billion yuan, focusing on new materials [3]. - China Guoxin's investment in strategic emerging industries has reached nearly 80%, covering nine major fields, and it has developed specific guidelines for investment strategies [3]. Group 3: Strategic Development - The State-owned Assets Supervision and Administration Commission (SASAC) emphasizes orderly development in strategic emerging industries, transitioning from expansion to internal strengthening [5]. - The development of strategic emerging industries is moving from the initial stage to a more advanced phase, with a focus on recognizing, investing, and practicing [5]. - Recommendations include precise boundary delineation for SOEs in emerging industries to reduce disorderly investments and resource waste [6].

Core Viewpoint - The company has received four medical device registration certificates from the National Medical Products Administration and the Guangdong Provincial Medical Products Administration for various diagnostic test kits [1] Group 1 - The company obtained registration for the Hepatitis E Virus IgM Antibody Test Kit (Magnetic Microparticle Chemiluminescence Method) [1] - The company received approval for the Hepatitis E Virus IgG Antibody Test Kit (Magnetic Microparticle Chemiluminescence Method) [1] - The company has been granted a registration certificate for the Zinc Determination Test Kit (PAPS Colorimetric Method) [1] - The company also received a registration certificate for the Direct Bilirubin Determination Test Kit (Heavy Nitrogen Salt Method) [1]